Mechanisms of Botulinum Toxin Type A Action on Pain
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic and other chronic pain disorders. In comparison with other conventional and non-conventional analgesic drugs, the greatest advantages of BoNT/A use are its sustained effect after a single application and its safety. Its efficacy in certain therapy-resistant pain conditions is of special importance. Novel results in recent years has led to a better understanding of its actions, although further experimental and clinical research is warranted. Here, we summarize the effects contributing to these advantageous properties of BoNT/A in pain therapy, specific actions along the nociceptive pathway, consequences of its central activities, the molecular mechanisms of actions in neurons, and general pharmacokinetic parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 1×
“The pharmacotherapeutic options for the treatment of chronic migraine and neuropathic pain are very limited, with certain antiepileptics and antidepressants [121,122], and the development of analgesics with novel mechanisms of action has proven to be extremely challenging [123].”
BackgroundBotulinum Toxin as a Biological Weapon: Medical and Public Health Management
Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., et al. (2001) · JAMA · doi:10.1001/jama.285.8.1059 · Cited by 1,814
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
Tsui, J. C., Jon Stoessl, A., Eisen, A., Calne, S., & Calne, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92070-2 · Cited by 810
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012658 · Cited by 768
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain
Cui, M., Khanijou, S., Rubino, J., & Aoki, K. R. (2004) · Pain · doi:10.1016/j.pain.2003.10.008 · Cited by 676
Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain
Ranoux, D., Attal, N., Morain, F., & Bouhassira, D. (2008) · Annals of Neurology · doi:10.1002/ana.21427 · Cited by 459
Adherence to oral migraine-preventive medications among patients with chronic migraine
Hepp, Z., Dodick, D. W., Varon, S. F., Gillard, P., Hansen, R. N., & Devine, E. B. (2015) · Cephalalgia · doi:10.1177/0333102414547138 · Cited by 433
Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity
Morenilla-Palao, C., Planells-Cases, R., García-Sanz, N., & Ferrer-Montiel, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311515200 · Cited by 425
Hepp, Z., Dodick, D. W., Varon, S. F., Chia, J., Matthew, N., Gillard, P., Hansen, R. N., & Devine, E. B. (2017) · Cephalalgia · doi:10.1177/0333102416678382 · Cited by 359
McMahon, H. T., Foran, P., Dolly, J. O., Verhage, M., Wiegant, V. M., & Nicholls, D. G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36614-1 · Cited by 298
Botulinum toxin A and chronic low back pain: A randomized, double-blind study
Foster, L., Clapp, L., Erickson, M., & Jabbari, B. (2001) · Neurology · doi:10.1212/wnl.56.10.1290 · Cited by 297
Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial
Yuan, R. Y., Sheu, J. J., Yu, J. M., Chen, W. T., Tseng, I. J., Chang, H. H., & Hu, C. J. (2009) · Neurology · doi:10.1212/01.wnl.0000345968.05959.cf · Cited by 281
Meng, J., Wang, J., Lawrence, G., & Dolly, J. O. (2007) · Journal of Cell Science · doi:10.1242/jcs.012211 · Cited by 267
Attal, N., de Andrade, D. C., Adam, F., Ranoux, D., Teixeira, M. J., Galhardoni, R., Raicher, I., Üçeyler, N., Sommer, C., & Bouhassira, D. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00017-x · Cited by 253
Meng, J., Ovsepian, S. V., Wang, J., Pickering, M., Sasse, A., Aoki, K. R., Lawrence, G. W., & Dolly, J. O. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5490-08.2009 · Cited by 251
The C Terminus of SNAP25 Is Essential for Ca2+-dependent Binding of Synaptotagmin to SNARE Complexes
Gerona, R. R. L., Larsen, E. C., Kowalchyk, J. A., & Martin, T. F. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6328 · Cited by 243
Burstein, R., Zhang, X., Levy, D., Aoki, K. R., & Brin, M. F. (2014) · Cephalalgia · doi:10.1177/0333102414527648 · Cited by 230
Kuriyama, A. (2012) · JAMA · doi:10.1001/jama.2012.505 · Cited by 218
A molecular machine for neurotransmitter release: synaptotagmin and beyond
Südhof, T. C. (2013) · Nature Medicine · doi:10.1038/nm.3338 · Cited by 202
Subcutaneous Injection of Botulinum Toxin A Is Beneficial in Postherpetic Neuralgia
Xiao, L., Mackey, S., Hui, H., Xong, D., Zhang, Q., & Zhang, D. (2010) · Pain Medicine · doi:10.1111/j.1526-4637.2010.01003.x · Cited by 199
Blumenfeld, A. M., Stark, R. J., Freeman, M. C., Orejudos, A., & Manack Adams, A. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0840-8 · Cited by 197
Botulinum Neurotoxins A and E Undergo Retrograde Axonal Transport in Primary Motor Neurons
Restani, L., Giribaldi, F., Manich, M., Bercsenyi, K., Menendez, G., Rossetto, O., Caleo, M., & Schiavo, G. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003087 · Cited by 194
OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
Cernuda-Morollón, E., Ramón, C., Martínez-Camblor, P., Serrano-Pertierra, E., Larrosa, D., & Pascual, J. (2015) · Pain · doi:10.1097/j.pain.0000000000000119 · Cited by 181
Gazerani, P., Pedersen, N. S., Staahl, C., Drewes, A. M., & Arendt-Nielsen, L. (2009) · Pain · doi:10.1016/j.pain.2008.10.005 · Cited by 174
Chen, Y., Geis, C., & Sommer, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4170-07.2008 · Cited by 164
Marinelli, S., Vacca, V., Ricordy, R., Uggenti, C., Tata, A. M., Luvisetto, S., & Pavone, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047977 · Cited by 163
Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A
Shimizu, T., Shibata, M., Toriumi, H., Iwashita, T., Funakubo, M., Sato, H., Kuroi, T., Ebine, T., Koizumi, K., & Suzuki, N. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.07.010 · Cited by 162
CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine
Cernuda‐Morollón, E., Martínez‐Camblor, P., Ramón, C., Larrosa, D., Serrano‐Pertierra, E., & Pascual, J. (2014) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12372 · Cited by 161
Evidence for Anterograde Transport and Transcytosis of Botulinum Neurotoxin A (BoNT/A)
Restani, L., Antonucci, F., Gianfranceschi, L., Rossi, C., Rossetto, O., & Caleo, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2618-11.2011 · Cited by 160
Botulinum toxins for the prevention of migraine in adults
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J. A., Ives, N. J., Clarke, C. E., & Sinclair, A. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011616.pub2 · Cited by 156
Wang, T., Martin, S., Papadopulos, A., Harper, C. B., Mavlyutov, T. A., Niranjan, D., Glass, N. R., Cooper-White, J. J., Sibarita, J.-B., Choquet, D., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3757-14.2015 · Cited by 151
Botulinum Toxin A in Postherpetic Neuralgia
Apalla, Z., Sotiriou, E., Lallas, A., Lazaridou, E., & Ioannides, D. (2013) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e31827a72d2 · Cited by 134
The Role of the Synaptic Protein SNAP-25 in the Potency of Botulinum Neurotoxin Type A
Keller, J. E., & Neale, E. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010992200 · Cited by 130
Botulinum toxin treatment of pain syndromes –an evidence based review
Safarpour, Y., & Jabbari, B. (2018) · Toxicon · doi:10.1016/j.toxicon.2018.01.017 · Cited by 128
Favre‐Guilmard, C., Auguet, M., & Chabrier, P. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.047 · Cited by 127
Sandrini, G., Perrotta, A., Tassorelli, C., Torelli, P., Brighina, F., Sances, G., & Nappi, G. (2011) · The Journal of Headache and Pain · doi:10.1007/s10194-011-0339-z · Cited by 124
Bach‐Rojecky, L., Šalković‐Petrišić, M., & Lacković, Z. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.01.020 · Cited by 123
Self-citationZhao, Y.-L., Chen, S.-R., Chen, H., & Pan, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.378737 · Cited by 121
Pijpers, J. A., Kies, D. A., Louter, M. A., van Zwet, E. W., Ferrari, M. D., & Terwindt, G. M. (2019) · Brain · doi:10.1093/brain/awz052 · Cited by 113
Pozzi, D., Condliffe, S., Bozzi, Y., Chikhladze, M., Grumelli, C., Proux-Gillardeaux, V., Takahashi, M., Franceschetti, S., Verderio, C., & Matteoli, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706211105 · Cited by 111
Shehata, H., El‐Tamawy, M. S., Shalaby, N., et al. (2013) · The Journal of Headache and Pain · doi:10.1186/1129-2377-14-92 · Cited by 111
Botulinum Neurotoxin A Impairs Neurotransmission Following Retrograde Transynaptic Transport
Restani, L., Novelli, E., Bottari, D., Leone, P., Barone, I., Galli‐Resta, L., Strettoi, E., & Caleo, M. (2012) · Traffic · doi:10.1111/j.1600-0854.2012.01369.x · Cited by 107
Traffic of Botulinum Toxins A and E in Excitatory and Inhibitory Neurons
Verderio, C., Grumelli, C., Raiteri, L., Coco, S., Paluzzi, S., Caccin, P., Rossetto, O., Bonanno, G., Montecucco, C., & Matteoli, M. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00520.x · Cited by 106
Marinelli, S., Luvisetto, S., Cobianchi, S., Makuch, W., Obara, I., Mezzaroma, E., Caruso, M., Straface, E., Przewłocka, B., & Pavone, F. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.067 · Cited by 106
An update on new and unique uses of botulinum toxin in movement disorders
Jankovic, J. J. (2017) · Toxicon · doi:10.1016/j.toxicon.2017.09.003 · Cited by 106
Filipović, B., Matak, I., Bach‐Rojecky, L., & Lacković, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029803 · Cited by 103
Self-citationAnti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain
Luvisetto, S., Marinelli, S., Cobianchi, S., & Pavone, F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.12.004 · Cited by 100
A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A
Voller, B., Sycha, T., Gustorff, B., Schmetterer, L. F., Lehr, S., Eichler, H. G., Auff, E., & Schnider, P. (2003) · Neurology · doi:10.1212/01.wnl.0000086374.92906.6a · Cited by 95
Kitamura, Y., Matsuka, Y., Spigelman, I., Ishihara, Y., Yamamoto, Y., Sonoyama, W., Kuboki, T., & Oguma, K. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.066 · Cited by 91
The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain
Park, H. J., Lee, Y., Lee, J., Park, C.-M., & Moon, D. E. (2006) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03022619 · Cited by 90
Muraro, L., Tosatto, S. C. E., Motterlini, L., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.037 · Cited by 90
Mika, J., Rojewska, E., Makuch, W., Korostyński, M., Luvisetto, S., Marinelli, S., Pavone, F., & Przewłocka, B. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.11.040 · Cited by 86
Persistence of Botulinum Neurotoxin A Subtypes 1-5 in Primary Rat Spinal Cord Cells
Whitemarsh, R. C. M., Tepp, W. H., Johnson, E. A., & Pellett, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090252 · Cited by 85
Jacky, B., Garay, P. E., Dupuy, J., Nelson, J. B., Cai, B. B., Molina, Y., Wang, J., Steward, L. E., Broide, R. S., Francis, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003369 · Cited by 84
Huang, X. (1998) · Molecular Endocrinology · doi:10.1210/me.12.7.1060 · Cited by 83
Żychowska, M., Rojewska, E., Makuch, W., Luvisetto, S., Pavone, F., Marinelli, S., Przewłocka, B., & Mika, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.09.019 · Cited by 79
Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A
Drinovac, V., Bach‐Rojecky, L., Matak, I., & Lacković, Z. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.011 · Cited by 77
Self-citationDa Silva, L. F., DeSantana, J. M., & Sluka, K. A. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2009.08.006 · Cited by 77
Matak, I., Rossetto, O., & Lacković, Z. (2014) · Pain · doi:10.1016/j.pain.2014.04.027 · Cited by 77
Self-citationSingh, J. A., Mahowald, M. L., & Noorbaloochi, S. (2009) · Translational research · doi:10.1016/j.trsl.2009.02.004 · Cited by 77
Lacković, Z., Filipović, B., Matak, I., & Helyes, Z. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13366 · Cited by 75
Self-citationSingh, J. A., Mahowald, M. L., & Noorbaloochi, S. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100336 · Cited by 74
Piotrowska, A., Popiołek-Barczyk, K., Pavone, F., & Mika, J. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00141 · Cited by 68
The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes
Pellett, S., Bradshaw, M., Tepp, W. H., Pier, C. L., Whitemarsh, R. C. M., Chen, C., Barbieri, J. T., & Johnson, E. A. (2018) · mBio · doi:10.1128/mbio.00089-18 · Cited by 68
A molecular basis underlying differences in the toxicity of botulinum serotypes A and E
Bajohrs, M., Rickman, C., Binz, T., & Davletov, B. A. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400278 · Cited by 67
Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018
Loder, E., & Rizzoli, P. B. (2018) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13375 · Cited by 65
Arendt‐Nielsen, L., Jiang, G.-L., DeGryse, R. E., & Turkel, C. (2016) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2016.1203988 · Cited by 63
Botulinum Neurotoxin Type A Induces TLR2-Mediated Inflammatory Responses in Macrophages
Kim, Y. J., Kim, J.-H., Lee, K.-J., Choi, M., Kim, Y. H., Rhie, G., Yoo, C., Cha, K., & Shin, N.-R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120840 · Cited by 59
Persistence of Botulinum Neurotoxin Inactivation of Nerve Function
Shoemaker, C. B., & Oyler, G. A. (2012) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-33570-9_9 · Cited by 58
Vacca, V., Marinelli, S., Luvisetto, S., & Pavone, F. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.01.088 · Cited by 57
Botulinum Toxin Type A Reduces Hyperalgesia and TRPV1 Expression in Rats with Neuropathic Pain
Xiao, L., Cheng, J., Zhuang, Y., Qu, W., Muir, J. J., Liang, H., & Zhang, D. (2013) · Pain Medicine · doi:10.1111/pme.12017 · Cited by 55
Chen, S., Prunean, A., Pan, H.-M., Welker, K. L., & Pan, H. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.12.016 · Cited by 49
Challenges to develop novel anti‐inflammatory and analgesic drugs
Botz, B., Bölcskei, K., & Helyes, Z. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1427 · Cited by 48
Self-citationHong, B., Yao, L., Ni, L., Wang, L., & Hu, X. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.06.004 · Cited by 43
Botulinum neurotoxin type A modulates vesicular release of glutamate from satellite glial cells
da Silva, L. B., Poulsen, J. N., Arendt‐Nielsen, L., & Gazerani, P. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12562 · Cited by 42
Lee, M. J., Lee, C., Choi, H., & Chung, C. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.054 · Cited by 40
Raciborska, D. A., & Charlton, M. P. (1999) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-77-9-679 · Cited by 39
Khavari, R., Elias, S. N., Pande, R., Wu, K. M., Boone, T. B., & Karmonik, C. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.07.066 · Cited by 36
Botulinum toxin A does not alter capsaicin-induced pain perception in human skin
Schulte‐Mattler, W., Opatz, O. S., Blersch, W., et al. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.03.023 · Cited by 35
Anand, P., Anand, U., Ottó, Sinisi, M., Fox, Birch, Foster, K., Mukerji, Akbar, A., Agarwal, et al. (2011) · Journal of Pain Research · doi:10.2147/jpr.s25189 · Cited by 34
Vacca, V., Marinelli, S., Eleuteri, C., Luvisetto, S., & Pavone, F. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.01.002 · Cited by 31
Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics
Davies, J. R., Liu, S. M., & Acharya, K. R. (2018) · Toxins · doi:10.3390/toxins10100421 · Cited by 31
McAlindon, T. E., Schmidt, U., Bugarin, D., Abrams, S., Geib, T., DeGryse, R. E., Kim, K., & Schnitzer, T. J. (2018) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2018.05.001 · Cited by 30
Meyer‐Frießem, C. H., Eitner, L., Kaisler, M., Maier, C., Vollert, J., Westermann, A., Zahn, P. K., & González, C. A. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1626228 · Cited by 27
Reversal of Morphine Analgesic Tolerance by Ethanol in the Mouse
Hull, L. C., Gabra, B. H., Bailey, C. P., Henderson, G., & Dewey, W. L. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.202184 · Cited by 26
Young, W. B., Lopez, J. I., Rothrock, J. F., Orejudos, A. C., Adams, A. M., Lipton, R. B., & Blumenfeld, A. M. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0952-1 · Cited by 24
Megighian, A., Scorzeto, M., Zanini, D., Pantano, S., Rigoni, M., Benna, C., Rossetto, O., Montecucco, C., & Zordan, M. A. (2010) · Journal of Cell Science · doi:10.1242/jcs.071316 · Cited by 23
Intrinsic calcium dynamics control botulinum toxin A susceptibility in distinct neuronal populations
Grumelli, C., Corradini, I., Matteoli, M., & Verderio, C. (2010) · Cell Calcium · doi:10.1016/j.ceca.2010.03.002 · Cited by 16
Septins: Regulators of Protein Stability
Vagin, O., & Beenhouwer, D. O. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00143 · Cited by 11
Piovesan, É. J., Oshinsky, M. L., Silberstein, S. D., Kowacs, P. A., Nóvak, E. M., & Werneck, L. C. (2016) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20160067 · Cited by 5
Metadata
- Authors
- Matak, I., Bölcskei, K., Bach-Rojecky, L., & Helyes, Z.
- Venue
- Toxins
- Publisher
- MDPI AG
- Published
- 2019-08-05
- Volume
- 11
- Issue
- 8
- Pages
- 459
- ISSN
- 2072-6651 (ISSN-L)
- OpenAlex
- W2965226820
- Cited by
- 267
- References
- 91
- FWCI
- 15.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.